Pfizer Inc. $PFE Position Decreased by Atria Wealth Solutions Inc.

Key Points

• Atria Wealth Solutions Inc. reduced its holdings in Pfizer Inc. by 66.1% in the second quarter, now owning 195,671 shares valued at approximately $4.78 million.
• Several institutional investors have made adjustments to their Pfizer positions, with notable increases from Capital Advisory Group (up 2.9%) and Citizens National Bank Trust (up 0.9%).
• Pfizer announced a quarterly dividend of $0.43 per share, reflecting an annualized yield of 7.0%, with a dividend payout ratio of 91.49%.

Atria Wealth Solutions Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 66.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 195,671 shares of the biopharmaceutical company's stock after selling 381,972 shares during the period. Atria Wealth Solutions Inc.'s holdings in Pfizer were worth $4,781,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in PFE. Capital Advisory Group Advisory Services LLC boosted its holdings in shares of Pfizer by 2.9% in the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after buying an additional 388 shares during the period. Citizens National Bank Trust Department raised its holdings in shares of Pfizer by 0.9% during the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock valued at $1,118,000 after acquiring an additional 395 shares during the period. Trust Co of the South raised its holdings in shares of Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock valued at $712,000 after acquiring an additional 441 shares during the period. Charter Oak Capital Management LLC raised its holdings in shares of Pfizer by 4.3% during the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock valued at $258,000 after acquiring an additional 444 shares during the period. Finally, Ballentine Partners LLC raised its holdings in shares of Pfizer by 0.5% during the second quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company's stock valued at $2,260,000 after acquiring an additional 458 shares during the period. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PFE shares. Citigroup boosted their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Bank of America raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 3rd. Morgan Stanley lowered their price objective on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $28.35.

Pfizer Price Performance

Shares of PFE opened at $24.72 on Tuesday. The firm has a market cap of $140.52 billion, a PE ratio of 13.15, a PEG ratio of 0.82 and a beta of 0.55. The firm's 50 day moving average price is $24.88 and its 200 day moving average price is $24.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.82.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.